The Fly | BTTC

Focus on Chronic Disease Management: The company targets therapeutic areas like Parkinson's disease where long-term, consistent drug delivery can significantly improve patient outcomes.

Potential for Enhanced Patient Adherence: ProNeura's implantable nature reduces the need for daily dosing, potentially leading to higher patient compliance.

Going Concern and Liquidity Risk: Titan Pharmaceuticals Inc. has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern without securing additional funding or achieving significant product sales.

Product Commercialization and Market Adoption Risk: The commercialization of Probuphine, their primary product, has faced significant challenges, including limited market acceptance and sales, which could hinder revenue generation and profitability.

Reliance on a Single Product Risk: The company's revenue and future prospects are heavily dependent on the success of Probuphine, with a limited pipeline of other clinical-stage products, making it vulnerable to market shifts or product-specific issues.

Charts

Proprietary Drug Delivery Platform: Titan's ProNeura technology offers a unique, sustained drug delivery system for chronic conditions.

Focus on Chronic Disease Management: The company targets therapeutic areas like Parkinson's disease where long-term, consistent drug delivery can significantly improve patient outcomes.

Potential for Enhanced Patient Adherence: ProNeura's implantable nature reduces the need for daily dosing, potentially leading to higher patient compliance.